The vaccine against Covid-19 developed by the English university of Oxford with the pharmacist AstraZeneca has acceptable levels of security and is effective according to preliminary results of Phase 3 of clinical trials published this Tuesday in the journal "The Lancet."
The Oxford experts today published, for the first time, the conclusions of their clinical trials, which showed an absence of hospitalizations or "severe illness" in the individuals in the vaccinated group.
These results on the clinical efficacy of the drug (AZD1222) -reviewed by other independent experts- come from the analysis of a pre-specific group of Phase 3 carried out in the United Kingdom and Brazil with 11,636 subjects, to which is added "security data" of a total of 23,745 individuals tested in four tests developed in the United Kingdom, Brazil and South Africa.
The Oxford team, led by Andrew Pollard and Sarah Gilbert, found that their vaccine, given in two doses (preparatory and reinforcement), it is effective in an average of 70%, although the variation in the amount of each dose affects the result. Thus, when half a dose is administered followed by a full dose, the efficacy level of the vaccine rises to 90% and falls to 62% when volunteers receive two full doses of the preparation.
Among the 23,745 immunized people, only three in a median period of 3.4 months experienced "serious adverse effects" that could be attributed to the vaccine, although all have recovered or are recovering and continue to participate in clinical trialsOxford experts explained in a statement.
"In future analyzes, with the inclusion of more data As they become available, we will investigate differences in key subgroups -such as older adults-, various ethnicities, doses, times of administration of booster vaccines, and thus we will determine which immune responses offer protection against infections or diseases, "said Merryn Voysey, one of the study authors.
Pollard, for his part, stressed that "the efficacy of our vaccine" has exceeded the thresholds set by the health authorities, including those of the European Union (EU), which has yet to give its approval to this drug. "We will only be able to control the pandemic if the licensing, manufacturing and distribution of these vaccines can be carried out on an unprecedented scale, and the vaccination process reaches the most vulnerable," said the Oxford scientist.
AZD1222 has been made from the genetic modification of a common cold virus that affects chimpanzees, but does not cause disease in humans and is capable of expressing the S protein of SARS-CoV-2, the coronavirus that causes covid .
. (tagsToTranslate) vaccine (t) Oxford (t) AstraZeneca (t) effective (t) safe (t) according to (t) proven (t) results (t) Category: All (t) Category: Europe Report (t) Category : International News (t) Category: Others (t) Category: Pulsos (t) Category: Pulsos Europa (t) mostread_ultimas (t) mostread_fundsnews (t) mostread_internacional